← Leaderboards
David G Maloney
Fred Hutchinson Cancer Research Center
$3,575,748
Attributed
$3,575,748
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $263.7K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,575,748 · 4
By mechanism
P01$2,794,363 · 3
R01$781,385 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Brenda Marie Sandmaier$22,185,663
- Rainer F. Storb$23,835,935
- Johnnie Jose Orozco$5,851,901
- John M. Pagel$5,647,981
- Oliver W. Press$23,607,906
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorConditioningTransplantationEngraftmentAntibodiesDoseRelapseToxic EffectHematopoieticFludarabineAllogenicProliferatingAutologousNatural ImmunosuppressionChimerismAllograftingHigh RiskImmunologicsPeripheral Blood Stem CellGraft Vs Tumor EffectCellsGrantMortality Vital StatisticsCsf3 Gene
Grant awards (18)
Project 3: Stem Cell Allografts for Lymphoid Malignancies$122,776
P01 · FY2018 · CA · contact PI
Project 3: Stem Cell Allografts for Lymphoid Malignancies$257,616
P01 · FY2017 · CA · contact PI
Project 3: Stem Cell Allografts for Lymphoid Malignancies$257,616
P01 · FY2016 · CA · contact PI
Project 3: Stem Cell Allografts for Lymphoid Malignancies$257,616
P01 · FY2015 · CA · contact PI
Project 3: Stem Cell Allografts for Lymphoid Malignancies$263,671
P01 · FY2014 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Pharmacologic Manipulations$176,157
P01 · FY2013 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Pharmacologic Manipulations$182,361
P01 · FY2012 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Pharmacologic Manipulations$184,831
P01 · FY2011 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Pharmacologic Manipulations$185,605
P01 · FY2010 · CA · contact PI
Allogeneic HCT for Hematologic Malignancies: Pharmacologic Manipulations$222,005
P01 · FY2009 · CA · contact PI
Mixed Chimerism in the Treatment of B-Cell Malignancies$193,569
P01 · FY2008 · CA · contact PI
Mixed Chimerism in the Treatment of B-Cell Malignancies$191,797
P01 · FY2007 · CA · contact PI
Mixed Chimerism in the Treatment of B-Cell Malignancies$102,539
P01 · FY2006 · CA · contact PI
Mixed Chimerism in the Treatment of B-Cell Malignancies$99,552
P01 · FY2005 · CA
Mixed Chimerism in the Treatment of B-Cell Malignancies$96,652
P01 · FY2004 · CA
ANTI-CD20 ANTIBODY THERAPY OF NHL-- MECHANISM OF ACTION$268,197
R01 · FY2002 · CA
ANTI-CD20 ANTIBODY THERAPY OF NHL-- MECHANISM OF ACTION$260,387
R01 · FY2001 · CA
ANTI-CD20 ANTIBODY THERAPY OF NHL-- MECHANISM OF ACTION$252,801
R01 · FY2000 · CA